Clinical Trial Update: Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP 215 with bevacizumab in advanced non-small cell lung cancer has completed. Results were posted in October 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABP 215
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Amgen | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 3 | Status: COMPLETED | Results posted: 2017-10-19